These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6537690)

  • 1. Effect of calcitonin on hemodialysis patients with hypercalcemia and renal osteodystrophy.
    Carney SL; Epstein MT
    Uremia Invest; 1984-1985; 8(2):97-101. PubMed ID: 6537690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
    Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 6. A trial of calcitonin therapy in renal osteodystrophy.
    Delano BG; Baker R; Gardner B; Wallach S
    Nephron; 1973; 11(5):287-93. PubMed ID: 4753519
    [No Abstract]   [Full Text] [Related]  

  • 7. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
    Piraino B; Chen T; Puschett JB
    Am J Nephrol; 1989; 9(3):190-7. PubMed ID: 2757078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 11. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy?
    Ionova D; Zlatarska S; Kirjakov Z
    Nephrol Dial Transplant; 1995; 10(9):1782. PubMed ID: 8559512
    [No Abstract]   [Full Text] [Related]  

  • 12. [Influence of vitamin D therapy on renal osteodystrophy in children (author's transl)].
    Bulla M; Stock GJ; Delling G; Hofmann H; Offermann G
    Klin Wochenschr; 1980 Mar; 58(5):237-47. PubMed ID: 6249957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy].
    Di Landro D; Zanatta GP; Simioni N; Pinzani A; Zotti D; Perin N; Bertoli M; Naso A; Ruffatti A; Gasparotto ML
    Minerva Med; 1985 Mar; 76(9-10):419-23. PubMed ID: 3982699
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium metabolism in renal failure.
    David DS
    Am J Med; 1975 Jan; 58(1):48-56. PubMed ID: 1090150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX; Li H
    Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
    Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
    Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
    [No Abstract]   [Full Text] [Related]  

  • 17. [Calcitonin for therapy of renal osteodystrophy due to long-term hemodialysis in patients with chronic kidney failure].
    Ishida M; Yamada M
    Nihon Rinsho; 1991 Dec; 49 Suppl():725-31. PubMed ID: 1808343
    [No Abstract]   [Full Text] [Related]  

  • 18. Spontaneous hypercalcemia in patients undergoing dialysis. Etiologic and therapeutic considerations.
    Piraino BM; Rault R; Greenberg A; Dominguez JH; Wallia R; Houck P; Segre GV; Chen T; Foti FM; Puschett JB
    Am J Med; 1986 Apr; 80(4):607-15. PubMed ID: 3963041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
    Shusterman NH; Wasserstein AG; Morrison G; Audet P; Fallon MD; Kaplan F
    Am J Med; 1987 Jun; 82(6):1148-56. PubMed ID: 3605132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of phosphate depletion and high dialysate calcium in controlling dialytic renal osteodystrophy.
    Goldsmith RS; Johnson WJ
    Kidney Int; 1973 Aug; 4(2):154-60. PubMed ID: 4744973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.